Closing the Medication-Assisted Treatment Gap for Youth With Opioid Use Disorder
In years past, an adolescent patient presenting to primary care with symptoms of opioid use disorder (OUD) would have been a highly rare event in most communities. With OUD and fatal overdoses rising among adolescents and young adults (termed youth) over the past 15 years, this scenario has unfortunately become more common. Fatal drug overdoses […]
Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014
In this large, national retrospective cohort of 20 822 youth aged 13 to 25 years with opioid use disorder, medication receipt increased from 2001 to 2014, but only 1 in 4 individuals received buprenorphine or naltrexone. Younger individuals, females, and black and Hispanic youth were less likely to receive a medication. Read abstract ›
Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome
Current pharmacologic treatment of the neonatal abstinence syndrome with morphine is associated with a lengthy duration of therapy and hospitalization. Buprenorphine may be more effective than morphine for this indication. Read abstract ›
“All Scientific Hands on Deck” to End the Opioid Crisis
By Nora Volkow (Director, NIDA) and Francis Collins (Director, NIH) In 2015, two million people had a prescription opioid use disorder and 591,000 suffered from a heroin use disorder; prescription drug misuse alone cost the nation $78.5 billion in healthcare, law enforcement, and lost productivity. But while the scope of the crisis is staggering, it […]
